Value Driven Drug Development

An estimated two-thirds of drugs fail to meet revenue expectations in their first year. Arrival at regulatory approval with limited evidence of real-world cost effectiveness and suboptimal prioritization of that evidence payers require to support HTA and reimbursement will delay market access.

The Value Driven Development Model

• ICON’s value driven development model helps you overcome some of the challenges of developing and commercializing the right drug for the right patient, given at the right time.  Our approach applies multidisciplinary expertise early in drug development to define, capture and communicate the clinical and commercially relevant evidence that demonstrates your product’s full value.
• With a focus on key value drivers, we help prioritize evidence generation to meet the needs of all relevant stakeholders in target markets to ensure development goals are aligned to a reimbursable TPP.  A return
• on investment lens guides product progression and investment decisions from proof-of-concept to loss of exclusivity.
• We deploy our multi-discipline experts based on your needs. These experts in portfolio strategy, health economics, epidemiology, outcomes research, and pricing and market access collaborate with your teams for an integrated, holistic approach to development that yields better regulatory and commercial results.